Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

IF 0.7 4区 医学 Q4 HEMATOLOGY Indian Journal of Hematology and Blood Transfusion Pub Date : 2023-10-01 Epub Date: 2023-01-04 DOI:10.1007/s12288-022-01623-0
Zeynep Arzu Yegin, Emine Merve Savaş, Şeyma Yıldız, Münevver İrem Kök, Meltem Büşra Erdemir, Başak Bostankolu Değirmenci, Zübeyde Nur Özkurt, Münci Yağcı
{"title":"Preconditioning Modified-Easix as a Predictor of Prognosis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.","authors":"Zeynep Arzu Yegin,&nbsp;Emine Merve Savaş,&nbsp;Şeyma Yıldız,&nbsp;Münevver İrem Kök,&nbsp;Meltem Büşra Erdemir,&nbsp;Başak Bostankolu Değirmenci,&nbsp;Zübeyde Nur Özkurt,&nbsp;Münci Yağcı","doi":"10.1007/s12288-022-01623-0","DOIUrl":null,"url":null,"abstract":"<p><p>Allogeneic hematopoietic stem cell transplantation (alloHCT) is associated with severe complications, most of which share a common physiopathological background characterized by endothelial dysfunction. A novel risk assessment model, endothelial activation and stress index (EASIX), has been introduced as a predictor of endothelial activation. This retrospective study was performed to evaluate the predictive impact of EASIX/modified-EASIX (mEASIX) on transplant outcome. Medical records of 398 alloHCT recipients [median age: 43(17-71) years; M/F: 243/155] were examined. EASIX/mEASIX were calculated at specific time points before and after transplantation. EASIX/mEASIX were significantly associated with transplant complications including engraftment syndrome, sinusoidal obstruction syndrome, febrile neutropenia and transplant associated thrombotic microangiopathy. The probability of overall survival was significantly higher in low-preconditioning mEASIX (day -7) group (37% vs 25.2%; <i>p</i> = 0.008; HR: 2.057; 95% CI: 1.208-3.504). The probabilities of day30 mortality (2.9% vs 19.4%; <i>p</i> = 0.017; HR: 7.028; 95% CI: 1.418-34.836), day100 mortality (9% vs 33%; <i>p</i> = 0.004; HR: 4.469; 95% CI: 1.619-12.336) and non relapse mortality (44.8% vs 61.4%; <i>p</i> = 0.005; HR: 2.551; 95% CI: 1.318-4.941) were lower in low-preconditioning mEASIX (day -7) group. This retrospective cohort analysis demonstrates the significant impact of EASIX/mEASIX on transplant complications and survival. Prospective analyses are mandatory to assess the predictive role of EASIX/mEASIX in clinical practice.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542067/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-022-01623-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHCT) is associated with severe complications, most of which share a common physiopathological background characterized by endothelial dysfunction. A novel risk assessment model, endothelial activation and stress index (EASIX), has been introduced as a predictor of endothelial activation. This retrospective study was performed to evaluate the predictive impact of EASIX/modified-EASIX (mEASIX) on transplant outcome. Medical records of 398 alloHCT recipients [median age: 43(17-71) years; M/F: 243/155] were examined. EASIX/mEASIX were calculated at specific time points before and after transplantation. EASIX/mEASIX were significantly associated with transplant complications including engraftment syndrome, sinusoidal obstruction syndrome, febrile neutropenia and transplant associated thrombotic microangiopathy. The probability of overall survival was significantly higher in low-preconditioning mEASIX (day -7) group (37% vs 25.2%; p = 0.008; HR: 2.057; 95% CI: 1.208-3.504). The probabilities of day30 mortality (2.9% vs 19.4%; p = 0.017; HR: 7.028; 95% CI: 1.418-34.836), day100 mortality (9% vs 33%; p = 0.004; HR: 4.469; 95% CI: 1.619-12.336) and non relapse mortality (44.8% vs 61.4%; p = 0.005; HR: 2.551; 95% CI: 1.318-4.941) were lower in low-preconditioning mEASIX (day -7) group. This retrospective cohort analysis demonstrates the significant impact of EASIX/mEASIX on transplant complications and survival. Prospective analyses are mandatory to assess the predictive role of EASIX/mEASIX in clinical practice.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预处理改良Easix作为异基因造血干细胞移植受者预后的预测因子。
异基因造血干细胞移植(alloHCT)与严重并发症有关,其中大多数并发症具有以内皮功能障碍为特征的共同生理病理背景。一种新的风险评估模型,内皮细胞活化和应激指数(EASIX),已被引入作为内皮细胞活化的预测指标。本回顾性研究旨在评估EASIX/改良EASIX(mEASIX)对移植结果的预测影响。检查了398名同种异体HCT接受者的医疗记录[中位年龄:43(17-71)岁;男/女:243/155]。在移植前后的特定时间点计算EASIX/mEASIX。EASIX/mEASIX与移植并发症显著相关,包括植入综合征、窦梗阻综合征、发热性中性粒细胞减少症和移植相关血栓性微血管病。低预处理mEASIX(第7天)组的总生存概率显著较高(37%对25.2%;p = 0.008;小时:2.057;95%可信区间:1.208-3.504)。第30天死亡的概率(2.9%对19.4%;p = 0.017;小时:7.028;95%可信区间:1.418-34.836),第100天死亡率(9%对33%;p = 0.004;小时:4.469;95%可信区间:1.619-12.336)和无复发死亡率(44.8%vs 61.4%;p = 0.005;小时:2.551;95%可信区间1.318-4.941)较低。这项回顾性队列分析证明了EASIX/mEASIX对移植并发症和生存率的显著影响。前瞻性分析是强制性的,以评估EASIX/mEASIX在临床实践中的预测作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
82
审稿时长
>12 weeks
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
期刊最新文献
Clinico-Pathological Significance and Prognostic Impact of Various PML RARA Transcripts on Outcomes in Acute Promyelocytic Myeloid Leukemia (APML) Treated with Single Agent Arsenic Trioxide(ATO)- Insights from a Tertiary Cancer Center in South India When Eosinophils Speak: A Case of Strongyloides stercoralis Infection Navigating the Challenges of Bombay Phenotype (Oh) and Leukemia A Pedigree Investigation of H-antigen Deletion Caused by Mutation of 658 C to T in the FUT1 Gene. Haploidentical Hematopoietic Stem Cell Transplantation in India-Bridging the Gap.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1